Sanofi-Aventis Revenue Swells
Sanofi-Aventis (SNY) said Monday that full-year sales rose 9% to $33 billion as strong gains from its vaccine business and several signature products were partly offset by generic competition for several other drugs.
Fourth-quarter sales gained 5% to $8.46 billion.
The French company won't issue its earnings results until Feb. 24, although it said last year's earnings per share, excluding one-time items, should be about 25% higher than for 2004.
Meanwhile, many analysts are paying more attention to two big upcoming events that will have a major impact during the rest of the decade than to last year's and last quarter's sales and earnings.Next month, the Food and Drug Administration is supposed to rule on Acomplia, a proposed treatment for obesity and addiction to smoking that has made some analysts giddy with excitement. In April, Sanofi-Aventis will ask a U.S. court to prevent another company from selling a cheap, generic copy of the anticoagulant Plavix, the company's second-biggest product and the biggest-selling drug for its marketing partner Bristol-Myers Squibb (BMY). "Each
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV